GH - NASDAQ
Guardant Health, Inc.
$127.03
-2.4%Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
At a Glance
Live SnapshotGuardant Health, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Guardant Health, Inc. Income Statement
GH • NASDAQ
| Guardant Health, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||
982M | 739M | 563.9M | 449.5M | 373.7M | 286.7M | 214.4M | 90.6M | 49.8M | 25.2M | |
GROSS PROFIT | ||||||||||
(349M) | (289.8M) | (227.1M) | (156.3M) | (122.9M) | (92.5M) | (70.7M) | (43.2M) | (31.6M) | (22.1M) | |
633M | 449.2M | 336.9M | 293.2M | 250.7M | 194.2M | 143.7M | 47.4M | 18.2M | 3.1M | |
OPERATING INCOME | ||||||||||
(1.1B) | (892.8M) | (901.6M) | (837.6M) | (661.7M) | (449.1M) | (226M) | (140.4M) | (94.8M) | (47M) | |
(706.1M) | (545.1M) | (451M) | (463.8M) | (398.5M) | (299.3M) | (139.7M) | (89.7M) | (69.3M) | (36.1M) | |
(364.2M) | (347.8M) | (367.2M) | (373.8M) | (263.2M) | (149.9M) | (86.3M) | (50.7M) | (25.6M) | (10.9M) | |
-436.3M | -443.6M | -564.7M | -544.4M | -411M | -255M | -82.4M | -92.9M | -76.6M | -43.8M | |
PRE-TAX INCOME | ||||||||||
(3.9M) | (2.6M) | (2.6M) | (2.6M) | (2.6M) | (4.8M) | (1.2M) | (1.3M) | (2.7M) | (3M) | |
30.2M | 51.1M | 32.8M | 3.5M | 1.4M | 5.4M | 12.6M | 4M | -468K | -2.3M | |
(0.0) | (0.0) | (83.4M) | (0.0) | (0.0) | (0.0) | (88K) | (0.0) | (0.0) | -1K | |
18.8M | 8.5M | 86M | -109.1M | 26.5M | 9M | 12.6M | 8.7M | -6.6M | -2.3M | |
-417.5M | -435.1M | -478.8M | -653.4M | -384.5M | -245.9M | -69.7M | -84.2M | -83.2M | -46.1M | |
NET INCOME | ||||||||||
-1.3M | (1.3M) | (685K) | (1.1M) | (300K) | (379K) | -1.9M | (38K) | (7K) | (6K) | |
-416.3M | -436.4M | -479.4M | -654.6M | -405.7M | -253.8M | -75.7M | -85.1M | -83.2M | -46.1M |
SEC Filings
GH - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 19, 2026 | February 19, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 11, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 07, 2025 | November 04, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | October 29, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 29, 2025 | October 29, 2025 | 2025 |
Related Guides
Continue your GH research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.